TSINNARIZIN

Active material: Tsinnarizin
When ATH: N07CA02
CCF: A calcium channel blocker with advantageous effects on the brain vessels
When CSF: 01.03.04
Manufacturer: SOPHARMA AD (Bulgaria)

PHARMACEUTICAL FORM, COMPOSITION AND PACKAGING

Pills white or nearly white, round (diameter 7 mm), lenticular, without smell.

Excipients: wheat starch, lactose monohydrate, polyvinylpyrrolidone K25, aэrosyl 200, magnesium stearate, microcrystalline cellulose.

50 PC. – blisters (1) – packs cardboard.

Pharmacological action

According to current data, cinnarizine pharmacological properties are largely due to its ability to block the membrane calcium channels. It inhibits (suppresses) inflow of calcium ions into cells.

Cinnarizine positive effect on the brain, peripheral and coronary (cardiac) blood circulation; improves microcirculation. It enhances the ability of red blood cells to deform (increase plasticity) and reduces the hyperviscosity. It increases the resistance of tissues to hypoxia (insufficient supply of oxygen to tissues, or violation of its assimilation).
The drug has a direct antispasmodic (relieves spasms) action on blood vessels, reduces their response to biogenic vasoconstrictors. Potenziruet (increases) effects on the brain vessels of CO2 (Carbon Monoxide). On the systemic arterial pressure, heart rate, cardiac conduction and contractility did not significantly affect.
The drug also has antihistaminic activity. Reduces the excitability of the vestibular apparatus (brain structures, responsible for coordination), suppress nystagmus (involuntary movements of the eyeballs).

Indications

As cerebrovascular (affecting the blood vessels of the brain) means prescribed for cerebrovascular disorders, associated with spasm (a sharp narrowing of the lumen) vessels, atherosclerosis, migrated cranial trauma, stroke. The drug reduces the phenomenon cerebroasthenic (weakening of brain function), Headache, noise in ears, improves the general condition.
Assign Cinnarizinum migraine, Meniere's disease (disease of the inner ear).
Cinnarizine is also used to reduce spasms of peripheral blood vessels and improve circulation in obliteriruyushem endarteriite (inflammation of the inner lining of arteries with a decrease in their lumen), trombangiite (inflammation of the artery walls with their occlusion), Raynaud's disease (narrowing of the lumen of the vessels of the extremities), acrocyanosis (blue fingertips, lips, nose) and other violations of peripheral blood circulation.

Mode of application

Take Cinnarizinum inside after eating: in disorders of cerebral circulation – usually 25 mg (I таблетка) 3 twice daily or 75 mg (1 capsule) 1 once a day; in violation of the peripheral circulation – by 50-75 mg (2-3 tablets) 3 times a day, or 2-3 capsules (by 75 mg each) in a day. Use the drug with respect to long-term (rates from several weeks to several months).
When vestibular disorders is recommended to give at 25 mg 3 times during the day. In severe hypotension (low blood pressure) the drug is prescribed in small doses (0,025 g 2 once a day).

Side effects

The drug is generally well tolerated, sometimes possible moderate somnolence, dry mouth, gastrointestinal disorders; In these cases
reduce the dose. For some elderly patients appear (or worse) extrapyramidal symptoms (incoordination with decreasing volume and shake).
Cinnarizine increases the effects of sedatives (means, calming effect on the central nervous system) and alcohol. Possibility of sedation medication (especially in the first days of treatment) should be considered when administered- transport drivers and others, whose work requires quick mental and physical reactions.

Contraindications

It is not recommended to prescribe a drug for pregnant and breastfeeding.

Storage conditions

List B. In the dark place at room temperature.